From: Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer
n | % | RFS1 (P) | BRD2 (P) | n | % | RFS (P) | BRD (P) | ||
---|---|---|---|---|---|---|---|---|---|
T stage | 0.003 | 0.001 | Ad chemo TX 4 | 0.201 | 0.759 | ||||
T1 | 229 | 56.7 | Yes | 150 | 37.1 | ||||
T2 | 155 | 38.4 | No | 254 | 62.9 | ||||
T3 | 12 | 3.0 | Ad rad TX 5 | 0.851 | 0.906 | ||||
T4 | 8 | 2.0 | Yes | 295 | 73.0 | ||||
N stage | 0.036 | 0.001 | No | 109 | 27.0 | ||||
N0 | 261 | 64.6 | Ad hor TX 6 | 0.921 | 0.644 | ||||
N1 | 99 | 24.5 | Yes | 192 | 47.5 | ||||
N2 | 42 | 10.4 | No | 212 | 52.5 | ||||
N3 | 2 | 0.5 | Age | Continuous | 0.905 | 0.335 | |||
Stage | 0.008 | 0.001 | Menopausal status | 0.541 | 0.773 | ||||
I | 178 | 44.1 | Pre | 119 | 29.5 | ||||
IIA | 122 | 30.2 | Post | 212 | 52.5 | ||||
IIB | 53 | 12.3 | CTC | 0.029 | 0.001 | ||||
IIIA | 40 | 10.4 | Yes | 76 | 18.8 | ||||
IIIB | 9 | 1.7 | No | 328 | 81.2 | ||||
IIIC | 2 | 0.5 | Recurrence | ||||||
Histology | 0.933 | 0.440 | Yes | 54 | 13.4 | ||||
Lobular | 44 | 10.9 | No | 350 | 86.6 | ||||
Ductal | 341 | 84.4 | Mortality | ||||||
Other | 19 | 4.7 | Yes | 34 | 8.4 | ||||
Differentiation | <0.001 | <0.001 | No | 370 | 19.6 | ||||
I | 98 | 24.3 | BC mortality 7 | ||||||
II | 185 | 45.8 | Yes | 25 | 6.2 | ||||
III | 121 | 30.0 | No | 379 | 93.8 | ||||
ER 1 | 0.029 | <0.001 | Follow-up | ||||||
Pos | 342 | 84.7 | min | 6 months | |||||
Neg | 62 | 15.3 | max | 90 months | |||||
PR 2 | 0.061 | 0.001 | mean | 48.6 months | |||||
Pos | 290 | 71.8 | median | 48 months | |||||
Neg | 114 | 28.2 | |||||||
Her2/neu 3 | 0.024 | 0.010 | |||||||
Pos | 81 | 20.0 | |||||||
Neg | 323 | 80.0 |